UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Nature communications, 2020-05, Vol.11 (1), p.2641-18, Article 2641

2020

Volltextzugriff (PDF)

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

Molecular cancer, 2015-11, Vol.14 (9157), p.196-196, Article 196

2015

Volltextzugriff (PDF)

The Changing View of High-Grade Serous Ovarian Cancer

Cancer research (Chicago, Ill.), 2012-06, Vol.72 (11), p.2701-2704

2012

Volltextzugriff (PDF)

Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes

Breast cancer research and treatment, 2012-06, Vol.133 (3), p.843-851

2012

Volltextzugriff (PDF)

Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers

PloS one, 2015-12, Vol.10 (12), p.e0143178

2015

Volltextzugriff (PDF)

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer

Biomolecules (Basel, Switzerland), 2020-03, Vol.10 (3), p.415

2020

Volltextzugriff (PDF)

Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer

Cancer research (Chicago, Ill.), 2013-11, Vol.73 (22), p.6632-6641

2013

Volltextzugriff (PDF)

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

Breast cancer research and treatment, 2009-01, Vol.113 (2), p.275-283

2009

Volltextzugriff (PDF)

IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer

Oncogene, 2018-04, Vol.37 (14), p.1869-1884

2018

Volltextzugriff (PDF)

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer

Breast cancer research and treatment, 2009-07, Vol.116 (2), p.263-271

2009

Volltextzugriff (PDF)

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

Breast cancer research and treatment, 2013-05, Vol.139 (1), p.39-49

2013

Volltextzugriff (PDF)

TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer

Breast cancer research and treatment, 2009-01, Vol.113 (2), p.253-260

2009

Volltextzugriff (PDF)

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients

BMC cancer, 2016-02, Vol.16 (123), p.123-123, Article 123

2016

Volltextzugriff (PDF)

HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study

Journal of clinical oncology, 2007-02, Vol.25 (6), p.662-668

2007

Volltextzugriff (PDF)

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines

Breast cancer research and treatment, 2006-09, Vol.99 (1), p.97-101

2006

Volltextzugriff (PDF)

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

Journal of cancer research and clinical oncology, 2015-10, Vol.141 (10), p.1879-1887

2015

Volltextzugriff (PDF)

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

Genome medicine, 2015-10, Vol.7 (1), p.108-108, Article 108

2015

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Targeted oncology, 2015-12, Vol.10 (4), p.583-596

2015

Volltextzugriff (PDF)

MicroRNAs in ovarian cancer biology and therapy resistance

The international journal of biochemistry & cell biology, 2010-08, Vol.42 (8), p.1282-1290

2010

Volltextzugriff (PDF)

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

British journal of cancer, 2021-02, Vol.124 (4), p.777-785

2021

Volltextzugriff (PDF)

Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma

Head & neck, 2007-04, Vol.29 (4), p.341-350

2007

Volltextzugriff (PDF)

APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma

Clinical cancer research, 2016-09, Vol.22 (18), p.4746-4755

2016

Volltextzugriff (PDF)

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients

Breast cancer research : BCR, 2014-01, Vol.16 (1), p.R13-R13, Article R13

2014

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)

Publikationsform

Artikel
(116)

Sprache

Englisch
(116)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

The Changing View of High-Grade Serous Ovarian Cancer

Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes

Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer

Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients

HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

MicroRNAs in ovarian cancer biology and therapy resistance

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma

APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients

Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer

Aktive Filter

Suchergebnisse filtern